Get started

PHARMA

Long biased w/ recent settlement with Apotex and tight range.21-May-20 16:10 ET AMRN Amarin announces trial to evaluate effects of VASCEPA on patients with COVID-19 (7.28 -0.18) Amarin today announced support for a clinical trial to investigate the effects of icosapent ethyl (IPE) (VASCEPA) on inflammatory biomarkers and other patient outcomes in individuals with COVID-19. The trial primary endpoint is the effect of VASCEPA versus usual care on high-sensitivity C-reactive protein levels from baseline to 14 days in adults with a COVID-19-positive diagnosis. The clinical study design also includes other endpoints that assess rates and severity of COVID-19 infection in this high-risk group. The company states, "Based on our current understanding of the biological effects of a COVID-19 infection, including that patients at high risk of cardiovascular disease are at higher risk of mortality and severe effects from a COVID-19 infection, and based on data related to the mechanism of action and effects of VASCEPA in lowering cardiovascular risk in certain high-risk patients, it is believed that VASCEPA could play a beneficial clinical role in helping patients infected by the virus." 14-May-20 14:52 ET AMRN Amarin announces VASCEPA data from prespecified and post hoc analyses of REDUCE-IT study (7.64 +0.22) Amarin today announced that data from the REDUCE-IT study presented at the Society for Cardiovascular Angiography & Interventions 2020 Scientific Sessions,showed that administration of 4 g/day of VASCEPA (icosapent ethyl) resulted in a significant 34% reduction in first coronary revascularizations versus placebo (p<0.0001). Similar reductions of 36% were observed in total, or first and subsequent, revascularizations (p<0.0001). The analyses from the REDUCE-IT study included several types of coronary revascularization events in statin-treated patients with persistent elevated triglycerides (135-499 mg/dL), who also had either cardiovascular disease or diabetes and additional cardiovascular risk factors. Prespecified tertiary endpoint analyses showed that times to first revascularization events were significantly reduced by VASCEPA versus placebo across subtypes of intervention, including urgent, emergent, and elective revascularizations, which were reduced by 34% (p<0.0001), 38% (p=0.02), and 32% (p<0.0001), respectively. In post hoc analyses, VASCEPA significantly reduced percutaneous coronary intervention (PCI) by 32% (p<0.0001) and coronary artery bypass grafting (CABG) by 39% relative to placebo (p=0.0005).
NASDAQ:AMRNLong
by SwingingForward
$MNK One last HoorahTwo reasons for posting this chart. 1) MNK is a long standing established generic and specialty manufacturer with products that have real usage. This is NOT a one hit wonder biotech. It would be bought out before full bankruptcy. 2) More importantly, when was the last time you've seen a CLEAR bullish divergence on a MONTHLY chart? This will be a bag I hold probably until the end of 2020, but I expect it's first leg breaking out of its downtrend within the next 6 weeks. A Monthly bullish divergence MUST not be ignored. If you have money you are not actively trading with, THIS is where you put it. As you can see the accumulation volume over the last 6 months is there as well. Weekly has bullish divergences as well. On a shorter time frame, the daily is flagging. Breakout point 3.20 with target of 5 dollars.
MLong
by Matewan3291
5 Stocks we are looking into for the Covid-19 VaccineFirst off, please don't take anything I say seriously or as financial advice. As always, this is on an opinion based basis. That being said, let me get into my insights. There was rumors that AstraZeneca wanted to merge w/ Gilead. However, it looks like this may not happen. Until, the books are closed don't get your hopes up, but invest as if you expect something like this to go down. As far as stocks such as Pfizer, Pfizer so far is greatly underrated in terms of growth potential during the vaccine trials period, and likely because of that it is due for a bullish run quite soon. NVAX and Moderna, I believe already have the most stable growth potential given the logarithmic curves. These 5 stocks may be quite interesting to look at given all these giants from Pfizer to Moderna to Gilead are working on being the forefront of the expected Covid19 vaccine delivery. If this is a huge revenue booster, that means obvious profit turn over potential. Also, it is likely better for a buy entry previous to August, September, and the winter when hype may start increasing. Lots of the excitement have very recently slowed down, and you likely don't want to wait for the hype if you do long term holds.
NYSE:PFELong
by gamer456148
1
Pfizer Shizer; Do the Bears Have this One? 🏥 | PFIZER ($PFE)🧑‍⚕️ Pfizer recently announced that a clinical trial of its drug Ibrance hasn't worked out as a long-term treatment for breast cancer. This news is unfortunate on a few levels, but specifically, in terms of price, the impact isn't great. Upon releasing the news PFE dumped as analyst began to revise earnings expectations downward. This sell-off caused a reversal of the shorter term post-COVID downtrend and caused what appears to be a return to the pre-COVID downtrend. While we do think a short setup makes sense here given the facts, there is plenty of reason to be bullish from a longer-term point of view given Pfizer's projection that it could have a COVID vaccine by fall and given their funding of other COVID companies working on treatments. Resources: www.jpost.com + www.marketwatch.com + www.barrons.com ✨ Drop a comment asking for an update, we do NEW setups every day! ✨ Like, Comment & Follow to help the community grow 🎉🎉 --- 1. Fractal Trend is showing a fresh downtrend (Maroon colored bars) on the 1-hour timeframe. 2. With this strategy, we are looking for short setups in an downtrend and as such want to enter short on retests of bearish order blocks plotted by Orderblock Mapping (Maroon colored lines) and/or bearish S/R levels plotted by Directional Bias (Maroon colored lines). 3. The play here is simple, we are looking for a reaction at the R1 S/R flip and then are targeting the S1 orderblock at the current low. Then, by placing a stop just above the S/R flip, we have ourselves a solid 4.09 risk/reward ratio. 4. Other levels to the upside to watch here are R2 and R3 bearish orderblocks which should see a reaction if and when we move to the upside. 5. Below, the S2 and S3 bullish orderblocks should provide support if we move to the downside. Keep in mind we are only looking to short weakness in the near term here, as time goes on PFE should find support and potential COVID cures could easily send this stock back up. Until then, good luck bears!
NYSE:PFE
by AlphaBotSystem
1